4SC - Clinical Study Presentations at the 31. German Conference of Skin Cancer (31. Hautkrebskongress)
* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter stud…
* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter stud…
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that a Trial in Progress poster entitled: 1153TiP - A phase II, op…
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated…
. - Results from first nine patients include three objective responses - Two of these patients are progression-free >6…
Der Elan besitzt eine einzigartige, mikroprozessorgesteuerte Widerstandskontrolle und ermöglicht die unabhängige Steuer…
The market for platelet rich plasma (PRP) Europe is expected to reach US$ 37.5 Mn in 2016, up from US$ 35.3 Mn in 2015.…
Die Anforderungen der Prothesenanwender sind sehr unterschiedlich und variieren nach den jeweiligen Bedürfnissen. So ein…
End of November 2013 the leading competition for innovative wearable technologies, the Wearable Technologies Innovation…